Home › Funds › ProShares › Biotechnology Ultrasector Profund
Fund family: ProShares · Filed by ProFunds (CIK 1039803) · SEC series S000003107
Share classes and tickers: BIPIX (C000008429), BIPSX (C000008430)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 914 with, 6 against, 0 abstentions (not counted as with management). Shareholder proposals: 2 FOR, 4 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as ProShares’s manager page (303,945 ballot items across 135 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | ProShares | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 77.9% | 894 | 91.4% | 279,029 |
| Backed environmental and social shareholder proposals at US companies | n/a | 2 | 10.6% | 4,043 |
Each ballot item this fund voted is set against the votes of the other ProShares funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted the same way as most ProShares funds on all 818 items where a comparison was possible.
The same votes as “with management” above, by the sector of the company voted on. 97.2% of this fund’s 920 such votes could be given a sector; the other 26 (2.8%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 894 | 6 | 0.7% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 553 | 0 |
| Say-on-Pay | 142 | 0 |
| Audit-related | 129 | 0 |
| Compensation | 70 | 0 |
| Corporate Governance | 23 | 4 |
| Capital Structure | 18 | 0 |
| Extraordinary Transactions | 4 | 0 |
| Environment or Climate | 1 | 1 |
| Other Social Issues | 1 | 1 |
| Shareholder Rights and Defenses | 1 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Moderna, Inc. | May 6, 2026 | $12M | 5 | 0 |
| Moderna, Inc. | November 12, 2025 | $9M | 2 | 0 |
| TG Therapeutics, Inc. | June 11, 2026 | $3M | 8 | 0 |
| Twist Bioscience Corporation | February 5, 2026 | $3M | 5 | 0 |
| Travere Therapeutics, Inc. | May 19, 2026 | $3M | 14 | 0 |
| Revolution Medicines, Inc. | June 18, 2026 | $3M | 4 | 0 |
| Halozyme Therapeutics, Inc. | May 5, 2026 | $3M | 4 | 0 |
| Exelixis, Inc. | May 26, 2026 | $2M | 14 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 19, 2026 | Amgen Inc. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | For | Against |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | For | Against |
Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.
These funds reported the same votes as Biotechnology Ultrasector Profund in the latest season, so they share this page:
942 ballot items at 134 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Biotechnology Ultrasector Profund (BIPIX) voted at 134 shareholder meetings of 132 companies, on 942 ballot items in all. Where management made a recommendation, the fund followed it on 99.3% of the items and voted against it 6 times. Its most frequent area of disagreement was corporate governance (4 of its votes against management). It voted on 6 shareholder proposals. It voted FOR the board's own proposals less often than ProShares's funds as a whole (77.9% against 91.4%). It voted the same way as most ProShares funds on every item where a comparison was possible. 1 of its meetings was contested.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of ProShares’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.